Endothelin antagonists for chronic heart failure: Do they have a role?

European Heart Journal

Volumn 22, Issue 19, 2001, Pages 1772-1784

  Cowburn, Peter J ^a   Cleland, J G F ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; PHOSPHORAMIDON; SITAXSENTAN; TAK 044; TBC 11241; TEZOSENTAN; UNCLASSIFIED DRUG;

AMINO ACID BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; DRUG SELECTIVITY; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; KIDNEY FUNCTION; KIDNEY PERFUSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPLANCHNIC BLOOD FLOW;

ANIMALS; CHRONIC DISEASE; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 0034816975     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2557     Document Type: Review

References (141)

1. The obligatory role of endothelial cells in the relaxation of the arterial smooth muscle by acetylcholine
2. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
3. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
4. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
5. The endothelin family of peptides: Local hormones with diverse roles in health and disease?
6. Endothelins
7. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD)
8. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics
9. Neuroendocrine activation after myocardial infarction: Causes and consequences
10. Risk stratification in chronic heart failure
11. Effects of enalapril on mortality in severe chronic heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and chronic heart failure
13. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure
14. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
15. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
16. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
17. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
18. Guidelines for the management of heart failure
19. Consensus recommendations for the management of chronic heart failure
20. The effect of spironolactone on morbidity and mortality in patients with severe chronic heart failure
21. Successes and failures of current treatment of heart failure
22. The evidence for beta blockers in heart failure
23. Plasma endothelin levels in idiopathic dilated cardiomyopathy
24. Plasma endothelin in chronic heart failure
25. Plasma endothelin and pulmonary pressures in patients with congestive heart failure
26. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
27. Endothelin in human congestive heart failure
28. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
29. Endothelin in chronic heart failure: Current position and future prospects
30. Endothelin antagonists
31. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
32. A sensitive sandwich-enzyme immunoassay for human endothelin
33. Anatomical localisation and pharmacological activity of mature endothelins and their precursors in human vascular tissue
34. ECE-1: A membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1
35. Endothelin-converting enzyme-2 is a membrane bound, phosphoramidon sensitive metalloprotease with acidic pH optimum
36. Human endothelin-converting enzyme (ECE-1): Three isoforms with three distinct subcellular locations
37. A fourth isoenzyme of endothelin-converting enzyme (ECE-1a) is generated from an additional promoter-molecular cloning and characterisation
38. Purification of a membrane bound metalloendopeptidase from porcine kidney that degrades peptide hormones
39. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)
40. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo
41. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1
42. Cloning and expression of a cDNA encoding an endothelin receptor
43. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor
44. Cloning and expression of human endothelin-1 receptor cDNA
45. Identification of high affinity endothelin-1 receptor sub-types in human tissues
46. Molecular cloning of a non-isopeptide-selective human endothelin receptor
47. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: Evidence for expression of ET(B) receptors in human vascular smooth muscle
48. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
49. B receptor mediates both vasodilation and vasoconstriction in vivo
50. Endothelium-dependent modulation of responses to endothelin-1 in human veins
51. Both ET(A) and ET(B) receptors mediate contraction to edothelin-1 in human blood vessels
52. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
53. Cloning and characterisation of an endothelin-3 specific receptor (ETC) receptor from Xenopus laevis dermal melanophores
54. Cloning and characterisation of a novel endothelin receptor subtype in the avian class
55. Integrated cardiac, renal, and endocrine actions of endothelin
56. Endothelin is a potent long-lasting vasoconstrictor in man
57. Pharmacology of endothelin-1 in vivo in humans
58. Contribution of endogenous generation of endothelin-1 to basal vascular tone
59. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
60. Positive inotrope action of novel vasoconstrictor peptide endothelin on guinea pig atria
61. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation
62. Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle
63. Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction
64. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart
65. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure
66. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells
67. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells
68. Cardiorenal actions of endothelin, part 1: Effects of converting enzyme inhibition
69. Cellular mechanisms of endothelin-1 release by angiotensin and vasopressin
70. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo-role of ETA receptors for endothelin regulation
71. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition
72. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries
73. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells
74. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes
75. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells
76. The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion
77. A receptor antagonist, BQ-123, on ischaemic arrhythmias in anaesthetised rats
78. Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic
79. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670
80. Increased plasma concentrations of endothelin in congestive heart failure in humans
81. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
82. Elevated endothelin-1 in heart failure and loss of normal response to postural change
83. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
84. Elevated plasma endothelin concentrations in heart failure: An effect of angiotensin II?
85. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
86. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
87. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
88. Plasma endothelin in congestive cardiac failure: A predictor of cardiac death?
89. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
90. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
91. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
92. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension
93. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction
94. Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure
95. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: Acute effects of vasodilator therapy
96. Clearance of circulating endothelin-1 by ETB receptors in rats
97. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ET(B) receptors
98. Endothelin clearance in patients with chronic heart failure: Implications for anti-endothelin therapy
99. Down-regulation of ETB receptor, but not ETA receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ETB receptor-mediated clearance of endothelin-1?
100. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
101. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
102. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats
103. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction. Possible involvement of myocardial endothelin system in ventricular remodeling
104. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
105. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits
106. Chronic oral endothelin type A receptor antagonism in experimental heart failure
107. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
108. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure
109. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat
110. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure
111. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
112. Haemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
113. Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty
114. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
115. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe heart failure
116. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
117. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
118. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors
119. Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure
120. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
121. A receptor blockade in patients with congestive heart failure
122. B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction
123. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
124. Selective or non-selective endothelin receptor blockade in chronic heart failure?
125. A receptor antagonist
126. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
127. Xamoterol in severe heart failure
128. Effect of oral milrinone on mortality in severe chronic heart failure
129. Warning on Flosequinan
130. A randomised controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomised Survival Trial (FIRST)
131. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
132. B receptor antagonist in heart failure
133. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins
134. A receptor subtype-specific antagonist in healthy subjects
135. Receptor-mediated vascular and metabolic actions of endothelin-1 in canine small intestine
136. Novel selective quinazoline inhibitors of endothelin converting enzyme-1
137. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohormonal functions in congestive heart failure. Comparison of effects with those of endothelin A receptor antagonism
138. Update of REACH-I and MERIT-HF clinical trials in heart failure
139. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
140. Safety and efficacy of an orally active selective endothelin ETA receptor antagonist in moderate-severe human chronic heart failure
141. Results of a randomized, placebo-controlled, hemodynamic trial with an intravenous endothelin-1 receptor antagonist in patients with congestive heart failure